FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition

Comments
Loading...
  • The FDA has declined to approve AstraZeneca Plc's AZN asthma medicine, Fasenra (benralizumab), to treat chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and stuffiness.
  • The FDA has issued a complete response letter following AstraZeneca's application to extend the use of Fasenra and requested additional clinical data from it.
  • Fasenra raked in $1.26 billion in sales in 2021, jumping 33% from the previous year. 
  • The application by AstraZeneca included data from the OSTRO Phase III trial, which met both co-primary endpoints with a safety profile consistent with the known profile of the medicine. 
  • The CRL requested additional clinical data, and the Company is working closely with the FDA regarding the next steps. 
  • The Company remains committed to bringing Fasenra to patients with chronic rhinosinusitis with nasal polyps, and a second Phase III trial, ORCHID, in this indication is ongoing.
  • Price Action: AZN stock is up 1.82% at $61.40 during the market session on the last check Monday.
Overview Rating:
Speculative
37.5%
Technicals Analysis
66
0100
Financials Analysis
20
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!